Hostname: page-component-76fb5796d-45l2p Total loading time: 0 Render date: 2024-04-25T21:09:22.969Z Has data issue: false hasContentIssue false
  • English
  • Français

Will antimicrobial resistance of BRD pathogens impact BRD management in the future?

Published online by Cambridge University Press:  20 November 2014

Gordon W. Brumbaugh
Gordon W. Brumbaugh*
Affiliation:
Caine Veterinary Teaching Center, University of Idaho, Caldwell, Idaho, USA
*
Corresponding author. E-mail: gordonb@uidaho.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

Resistance is a qualitative interpretation of antimicrobial activity in vitro. Critical to management of bovine respiratory disease (BRD) is the clinical response in vivo. Attempts to connect activity in vitro to response in vivo have been complicated by the complexity of BRD, interpretation of antimicrobial activity in vitro, and inconsistent measures of clinical success or failure. During recent history, the discovery, development, and commercialization of antimicrobials have decreased. In response to resistance, voluntary and imposed restrictions on use of antimicrobials have been implemented. Resistance can be reversed using technology and knowledge of mechanisms of resistance. Perhaps approaches that reverse resistance will be used in clinical management of BRD in the future. The short answer to the question posed in the title is, ‘yes.’ Since antimicrobial drugs were discovered, resistance has been a consideration for selection of treatment of any infectious disease and BRD is not unique. In the opinion of the author, the more important question is, ‘How will antimicrobial resistance of BRD pathogens impact BRD management in the future?’

Keywords

bovine respiratory diseaseantimicrobial resistancepathogensclinical management
Type
Review Article
Information
Animal Health Research Reviews , Volume 15 , Issue 2 , December 2014 , pp. 175 - 177
Check for updates
Copyright
Copyright © Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abedon, ST, Kuhl, SJ, Blasdel, BG and Marin Kutter, E (2011). Phage treatment of human infections. Bacteriophage 1: 66–85.Google Scholar
Abuladze, T, Li, M, Menetrez, MY, Dean, T, Senecal, A and Sulakvelidze, A (2008). Bacteriophages reduce experimental contamination of hard surfaces, tomato, spinach, broccoli and ground beef by Escherichia coli O157:H7. Applied Environmental Microbiology 74: 6230–6238.Google Scholar
Apley, MD (2003). Susceptibility testing for bovine respiratory and enteric disease. Veterinary Clinics of North America, Food Animal Practice 19: 625–646.Google Scholar
Beceiro, A, Tomás, M and Bou, G (2013). Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? Clinical Microbiology Reviews 26: 185–230.CrossRefGoogle ScholarPubMed
Cirz, RT and Romesberg, FE (2006). Induction and inhibition of ciprofloxacin resistance-conferring mutations in hypermutator bacteria. Antimicrobial Agents and Chemotherapy 50: 220–225.Google Scholar
Clinical and Laboratory Standards Institute (CLSI) (2002a). Development of in vitro Susceptibility Testing Criteria and Quality Control Parameters for Veterinary Antimicrobial Agents; Approved Guideline, 3rd edn. CLSI document M37-A3.Wayne, Pennsylvania: CLSI.Google Scholar
Clinical and Laboratory Standards Institute (CLSI) (2002b). Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals; Approved Standard, 3rd edn. CLSI document M31-A3.Wayne, Pennsylvania: CLSI.Google Scholar
FDA (2013). Guidance for industry #213: new animal drugs and new animal drug combination products administered in or on medicated feed or drinking water of food-producing animal: recommendations for drug sponsors for voluntarily aligning product use conditions with GFI#209. [Available online at http://www.fda.gov/downloads/animalveterinary/guidancecomplianceenforcement/guidanceforindustry/ucm299624.pdf Last accessed May 20, 2014].Google Scholar
Giles, C and Shuttleworth, EM (1958). The sensitivity of various bacteria to antibiotics during the years 1951 to 1956. Journal of Clinical Pathology 11: 185–189.Google Scholar
Hong, Y, Pan, Y, Ebner, PD (2014). Meat science and muscle biology symposium: development of bacteriophage treatments to reduce Escherichia coli O157:H7 contamination of beef products and produce. Journal of Animal Science 92: 1366–1377.CrossRefGoogle ScholarPubMed
Jamieson, AM, Pasman, L, Yu, S, Gamradt, P, Homer, RJ, Decker, T and Medzhitov, R (2013). Role of tissue protection in lethal respiratory viral-bacterial coinfection. Science 340: 1230–1234.Google Scholar
Karriker, L (2007). The contribution and utility of case studies to evidence based medicine. Proceedings of the 38th Annual Meeting of the American Association of Swine Veterinarians; Orlando, FL: 17–18.Google Scholar
Katsuda, K, Kohmoto, M, Mikami, O and Uchida, I (2009). Antimicrobial resistance and genetic characterization of fluoroquinolone-resistant Mannheimia haemolytica isolates from cattle with bovine pneumonia. Veterinary Microbiology 139: 74–79.Google Scholar
Lamm, CG, Love, BC, Krehbiel, CR, Johnson, NJ and Step, DL (2012). Comparison of antemortem antimicrobial treatment regimens to antimicrobial susceptibility patterns of postmortem lung isolates from feedlot cattle with bronchopneumonia. Journal of Veterinary Diagnostic Investigation 24: 277–282.Google Scholar
Metlay, JP (2004). Antibacterial drug resistance: implications for the treatment of patients with community-acquired pneumonia. Infectious Disease Clinics of North America 18: 777–790.Google Scholar
McClary, DG, Loneragan, GH, Shryock, TR, Carter, BL, Guthrie, CA, Corbin, MJ and Mechor, GD (2011). Relationship of in vitro minimum inhibitory concentrations of tilmicosin against Mannheimia haemolytica and Pasteurella multocida and in vivo tilmicosin treatment outcome among calves with signs of bovine respiratory disease. Journal of the American Veterinary Medical Association 239: 129–135.Google Scholar
McPherson, CJ, Aschenbrenner, LM, Lacey, BM, Fahnoe, KC, Lemmon, MM, Finegan, SM, Tadakamalla, B, O'Donnell, JP, Mueller, JP and Tomaras, AP (2012). Clinically relevant Gram-negative resistance mechanisms have no effect on the efficacy of MC-1, a novel siderophore-conjugated monocarbam. Antimicrobial Agents and Chemotherapy 56: 6334–6342.CrossRefGoogle ScholarPubMed
O'Connor, AM, Wellman, NG, Rice, M and Funk, L (2010). Characteristics of clinical trials assessing antimicrobial treatment of bovine respiratory disease, 1970–2005. Journal of the American Veterinary Medical Association 237: 701–705.CrossRefGoogle ScholarPubMed
Rasko, DA and Sperandio, V (2010). Anti-virulence strategies to combat bacteria-mediated disease. Nature Reviews Drug Discovery 9: 117–128. doi: 10.1038/nrd3013Google Scholar
Ricci, V, Tzakas, P, Buckley, A, Coldham, NC and Piddock, LJV (2006). Ciprofloxacin-resistant Salmonella enterica serovar typhimurium strains are difficult to select in the absence of AcrB and TolC. Antimicrobial Agents and Chemotherapy 50: 38–42.Google Scholar
Rosenblatt-Farrell, N (2009). The landscape of antibiotic resistance. Environmental Health Perspectives 117: A245–A250.CrossRefGoogle ScholarPubMed
Silley, P (2012). Susceptibility testing methods, resistance and breakpoints: what do these terms really mean? Reviews in Science and Technology Office of International Epizootics 31: 33–41.Google Scholar
Simoens, S (2010). Cost-effectiveness and antimicrobial resistance in community-acquired pneumonia. Open Antimicrobial Agents Journal 2: 79–83.Google Scholar
Spellberg, B, Powers, JH, Brass, EP, Miller, LG and Edwards, JE (2004). Trends in antimicrobial drug development: implications for the future. Clinical Infectious Disease 38: 1279–1286.Google Scholar
Taylor, JD, Fulton, RW, Lehenbauer, TW, Step, DL and Confer, AW (2010a). The epidemiology of bovine respiratory disease: what is the evidence for predisposing factors? Canadian Veterinary Journal 51: 1095–1102.Google Scholar
Taylor, JD, Fulton, RW, Lehenbauer, TW, Step, DL and Confer, AW (2010b). The epidemiology of bovine respiratory disease: what is the evidence for preventive measures? Canadian Veterinary Journal 51: 1351–1359.Google Scholar
Tillotson, GS and Echols, RM (2008). Clinical trial design and consequences for drug development for community-acquired pneumonia: an industry perspective. Clinical Infectious Disease 47: S237–S240.Google Scholar
Vale, PF, Fenton, A, Brown, SP (2014). Limiting damage during infection: lessons from infection tolerance for novel therapeutics. PLoS Biology 12: e1001769. doi: 10.1371/journal.pbio.1001769.Google Scholar
Wright, GD (2013). Q&A: antibiotic resistance: what more do we know and what can we do? BMC Biology 11: 51–54.CrossRefGoogle Scholar